Medivir AB (MVIRb.F) Announces Initiation of the Second Cohort of the Interferon-Free Phase II Study Combining Simeprevir and Sofosbuvir for Hepatitis C Treatment
12/13/2012 9:53:16 AM
Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today the initiation of
cohort 2 in the interferon-free phase II trial combining simeprevir with
sofosbuvir (GS7977) based on a safety and efficacy planned interim analysis of
cohort 1 including prior null responder HCV genotype 1 infected patients without
advanced hepatic fibrosis. Data from the cohort 1 study will be presented at a
scientific conference during H1-2013.